

Improvement in Health-related Quality of Life With Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results From the KONFIDENT-S Study Stratified by Number of Treated Attacks

Presenter: William Lumry¹

Emel Aygören-Pürsün,² Aleena Banerji,^{3,4} Jonathan A. Bernstein,⁵ Danny M. Cohn,⁶ Henriette Farkas,⁷ Michael E. Manning,^{8,9} Daniel Soteres,¹⁰ Andrea Zanichelli,^{11,12} James Hao,¹³ Michael D. Smith,^{13*} Marc A. Riedl¹⁴

¹AARA Research Center, Dallas, TX, USA; ²University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany; ³Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA; ⁴Harvard Medical School, Boston, MA, USA; ⁵University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, OH, USA; ⁶Amsterdam University Medical Center, University of Amsterdam, Amsterdam; ⁷Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary; ⁸Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; ⁹University of Arizona College of Medicine-Phoenix, Scottsdale, AZ, USA; ¹⁰Asthma & Allergy Associates, PC and Research Center, Colorado Springs, CO, USA; ¹¹Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; ¹²Dipartimento di Scienze Biomediche per la Salute, University of Milan, Milan, Italy; ¹³KalVista Pharmaceuticals, a company of the Chiesi Group, Framingham, MA, USA (*former employee); ¹⁴University of California, San Diego, La Jolla, CA, USA

Disclosures

- Dr. William Lumry declares the following, real or perceived, conflicts of interest:
 - Receipt of grants/research support, honoraria, or consultation fees: KalVista Pharmaceuticals, Astria, BioCryst, BioMarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Magellan, Optum, Pharming, Pharvaris, Shire/Takeda, Optinose, Grifols, AstraZeneca, Sanofi/Regeneron, GSK, Ionis Pharmaceuticals, and Teva
 - Participation in sponsored speaker bureau: none
 - Stock/shareholder: none
 - Board membership with the US Hereditary Angioedema Association Medical Advisory Board and DFW Metroplex Allergy Society
- This trial was funded by KalVista Pharmaceuticals, a company of the Chiesi Group

Background and Objective



HAE is characterized by unpredictable, painful, and debilitating attacks that impair HRQoL¹



Greater reductions in HRQoL are observed when treatment is delayed or attacks are not treated²



Sebetralstat is the first and only oral on-demand therapy approved for patients with HAE aged ≥12 years in the US, UK, EU, Switzerland, Australia, Singapore, and Japan³

We present AE-QoL data from participants treating HAE attacks with sebetralstat in KONFIDENT-S

AE-QoL, angioedema quality of life; EU, European Union; HAE, hereditary angioedema; HRQoL, health-related quality of life; UK, United Kingdom; US, United States.

1. Yong PFK, et al. *Allergy Asthma Clin Immunol*. 2025;21:52. 2. O'Connor M, et al. *World Allergy Organ J*. 2025;18:101083. 3. KalVista Pharmaceuticals. Press Release. December 22, 2025. <https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-approval-ekterlyr> (accessed October 05, 2026).

KONFIDENT-S Study Design


- Eligible participants were ≥ 12 years of age with HAE-C1INH and had ≥ 2 documented attacks within 3 months, or had completed the phase 3 KONFIDENT trial¹
- Participants self-administered sebetralstat 600 mg as early as possible after attack onset
- Participants completed the AE-QoL questionnaire at enrollment (baseline) and in the eDiary every 28 (± 7) days thereafter
- The data cutoff for this analysis was September 30, 2025

AE-QoL²



17 items across 4 domains

Functioning • Fatigue/Mood •
Fears/Shame • Food



5-point Likert scale

Converted to a 0-100 scale;
Higher scores = greater QoL impairment




28-day recall period



Clinically meaningful change

MCID ≥ 6 points



Real-world Elements to Align With HAE Treatment Guidelines

- Portable multidose packs
- No need to contact a call center or investigator before, during, or after attacks
- Consider treatment of all attacks (any severity, any location)
- Self-administer 600 mg sebetralstat as early as possible^a

^aParticipants were instructed to treat their attacks involving the larynx immediately with conventional on-demand therapy if the attack symptoms worsened after the initial sebetralstat administration. AE-QoL, angioedema quality of life; HAE, hereditary angioedema; HAE-C1INH, hereditary angioedema due to C1 inhibitor deficiency; MCID, minimal clinically important difference.

1. Kinaciyan T, et al. *J Allergy Clin Immunol Glob*. 2026;5:100750. 2. Weller K, et al. *Allergy*. 2016;71(8):1203-1209.

Participant Demographics

	N=138
Age, mean (range), years	36.2 (12-77)
Sex, female, n (%)	90 (65)
Race, n (%)^a	
White	103 (75)
Asian	17 (12)
Other or Multiple	11 (8)
BMI, median (IQR), kg/m²	25.4 (22-31)
HAE-C1INH-Type 1, n (%)	129 (94)
Time since HAE diagnosis, median (IQR), years	12.1 (7-21)
Treatment regimen at screening, n (%)	
On-demand only	101 (73)
On-demand + LTP	37 (27)

126 participants
reported AE-QoL outcomes
(21 adolescents and 105 adults)

^aNot reported, 7 participants (5.1%).


BMI, body mass index; HAE, hereditary angioedema; HAE-C1INH, hereditary angioedema due to C1 inhibitor deficiency; IQR, interquartile range; LTP, long-term prophylaxis.

Sebetralstat-treated Attack Characteristics

	Sebetralstat-treated Attacks n=2469
Number of attacks per month, median (IQR)	1.04 (0.53-1.79)
Baseline pooled primary attack location, n (%) ^a	
Mucosal	1028 (44)
Laryngeal	49 (2)
Subcutaneous	1313 (56)
Baseline PGI-S rating, n (%) ^b	
Mild ^c	913 (39)
Moderate	985 (42)
Severe/Very severe	445 (19)

^aMissing: 128 (5.2%). ^bMissing: 126 (5.1%). ^cIncludes PGI-S rating "None": 45 (1.8%).
IQR, interquartile range; PGI-S, Patient Global Impression of Severity.


AE-QoL Improved From Baseline to Month 15 With Sebetralstat Treatment Regardless of Attack Frequency



For all participants in KONFIDENT-S, the locally estimated scatterplot smoothing (LOESS) fitted AE-QoL total score decreased from 35.9 at baseline to 28.7 at Month 15, a **clinically meaningful** improvement of -7.2


Participants who treated the **most attacks per month (Q4)** with sebetralstat showed the **greatest improvements in AE-QoL**

Clinically Meaningful (≥ 6 -Point) Improvements in AE-QoL Were Achieved Regardless of Attack Frequency



At Month 15, **45.2% of participants** achieved the MCID, a ≥ 6 -point reduction,¹ in LOESS fitted AE-QoL total score

AE-QoL Improved From Baseline to Month 15 With Sebetralstat Treatment Across Domains



At Month 15, the greatest changes were observed in the domains of **functioning** and **fears/shame**

Conclusions



On-demand treatment of HAE attacks with oral sebetrastat was associated with meaningful improvement in AE-QoL



45.2% of participants in KONFIDENT-S achieved a clinically meaningful improvement in LOESS fitted AE-QoL total score



The greatest AE-QoL score changes were observed in the domains of functioning and fears/shame



Participants who treated the highest number of attacks with sebetrastat experienced greater AE-QoL improvement

Acknowledgments

- KalVista thanks the people living with HAE and their families, patient advocates, and the investigator teams around the world who supported the KONFIDENT-S clinical trial
- Medical writing support was provided under the guidance of the authors by ApotheCom (San Francisco, CA, USA), and was funded by KalVista Pharmaceuticals, a company of the Chiesi Group